Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence
Left ventricular assist devices (LVADs) have been representing a cornerstone therapy for patients with end-stage heart failure during the last decades. However, their use induces several pathophysiological modifications which are partially responsible for the complications that typically characteriz...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/12/2/334 |
| _version_ | 1797482196177518592 |
|---|---|
| author | Carlotta Sciaccaluga Nicolò Ghionzoli Giulia Elena Mandoli Flavio D’Ascenzi Marta Focardi Serafina Valente Matteo Cameli |
| author_facet | Carlotta Sciaccaluga Nicolò Ghionzoli Giulia Elena Mandoli Flavio D’Ascenzi Marta Focardi Serafina Valente Matteo Cameli |
| author_sort | Carlotta Sciaccaluga |
| collection | DOAJ |
| description | Left ventricular assist devices (LVADs) have been representing a cornerstone therapy for patients with end-stage heart failure during the last decades. However, their use induces several pathophysiological modifications which are partially responsible for the complications that typically characterize these patients, such as right ventricular failure, thromboembolic events, as well as bleedings. During the last years, biomarkers involved in the pathways of neurohormonal activation, myocardial injury, adverse remodeling, oxidative stress and systemic inflammation have raised attention. The search and analysis of potential biomarkers in LVAD patients could lead to the identification of a subset of patients with an increased risk of developing these adverse events. This could then promote a closer follow-up as well as therapeutic modifications. Furthermore, it might highlight some new therapeutic pharmacological targets that could lead to improved long-term survival. The aim of this review is to provide current evidence on the role of different biomarkers in patients with LVAD, in particular highlighting their possible implications in clinical practice. |
| first_indexed | 2024-03-09T22:28:49Z |
| format | Article |
| id | doaj.art-43916f99cdf647d3b280928682ca9a87 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T22:28:49Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-43916f99cdf647d3b280928682ca9a872023-11-23T19:00:16ZengMDPI AGBiomolecules2218-273X2022-02-0112233410.3390/biom12020334Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current EvidenceCarlotta Sciaccaluga0Nicolò Ghionzoli1Giulia Elena Mandoli2Flavio D’Ascenzi3Marta Focardi4Serafina Valente5Matteo Cameli6Department of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyDepartment of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyDepartment of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyDepartment of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyDepartment of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyDepartment of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyDepartment of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, ItalyLeft ventricular assist devices (LVADs) have been representing a cornerstone therapy for patients with end-stage heart failure during the last decades. However, their use induces several pathophysiological modifications which are partially responsible for the complications that typically characterize these patients, such as right ventricular failure, thromboembolic events, as well as bleedings. During the last years, biomarkers involved in the pathways of neurohormonal activation, myocardial injury, adverse remodeling, oxidative stress and systemic inflammation have raised attention. The search and analysis of potential biomarkers in LVAD patients could lead to the identification of a subset of patients with an increased risk of developing these adverse events. This could then promote a closer follow-up as well as therapeutic modifications. Furthermore, it might highlight some new therapeutic pharmacological targets that could lead to improved long-term survival. The aim of this review is to provide current evidence on the role of different biomarkers in patients with LVAD, in particular highlighting their possible implications in clinical practice.https://www.mdpi.com/2218-273X/12/2/334LVADbiomarkersneurohormonal activationadverse remodelinginflammation |
| spellingShingle | Carlotta Sciaccaluga Nicolò Ghionzoli Giulia Elena Mandoli Flavio D’Ascenzi Marta Focardi Serafina Valente Matteo Cameli Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence Biomolecules LVAD biomarkers neurohormonal activation adverse remodeling inflammation |
| title | Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence |
| title_full | Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence |
| title_fullStr | Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence |
| title_full_unstemmed | Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence |
| title_short | Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence |
| title_sort | biomarkers in patients with left ventricular assist device an insight on current evidence |
| topic | LVAD biomarkers neurohormonal activation adverse remodeling inflammation |
| url | https://www.mdpi.com/2218-273X/12/2/334 |
| work_keys_str_mv | AT carlottasciaccaluga biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence AT nicologhionzoli biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence AT giuliaelenamandoli biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence AT flaviodascenzi biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence AT martafocardi biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence AT serafinavalente biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence AT matteocameli biomarkersinpatientswithleftventricularassistdeviceaninsightoncurrentevidence |